This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aratana (PETX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of -40.00% and 5.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Aratana (PETX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aratana (PETX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aratana (PETX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of -63.64% and -24.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Aratana Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Aratana Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Aratana Therapeutics (PETX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Aratana (PETX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of 246.15% and 278.16%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Aratana (PETX) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Aratana (PETX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aratana (PETX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aratana (PETX) delivered earnings and revenue surprises of 26.32% and 3.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Drug Stocks Poised to Surpass on Earnings This Quarter
by Zacks Equity Research
The outlook for the upcoming first-quarter results looks bright.
Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session
by Zacks Equity Research
Aratana Therapeutics (PETX) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.
Is a Surprise Coming for Aratana Therapeutics (PETX) This Earnings Season?
by Zacks Equity Research
Aratana Therapeutics (PETX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
by Zacks Equity Research
Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.
Intellipharmaceutics International (IPCI) Jumps: Stock Up 19%
by Zacks Equity Research
Intellipharmaceutics International Inc. (IPCI) shares rose around 19% in the last trading session.
Can Epizyme (EPZM) Spring a Surprise This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) is scheduled to report fourth-quarter 2016 results on Mar 9, before the opening bell.
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.
Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary, Elanco and partner Aratana Therapeutics, Inc. (PETX) together announced the availability of Galliprant for the management of pain and inflammation associated with canine osteoarthritis (OA).
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include PETX, AKS, ARIA, LSG and PVG.